Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland, March 26, 2025 /PRNewswire/ -- Vaximm AG, a...
Quantinuum Announces Generative Quantum AI Breakthrough with Massive Commercial Potential
Quantinuum Unveils Generative Quantum AI Framework that Harnesses Unique Quantum-Generated Data to Tackle Complex Problems Impossible for Classical Computing BROOMFIELD, Colo. and LONDON, Feb. 4, 2025 /PRNewswire/ -- Quantinuum today announced a...